pharmaceuticals
Field Reports
Obesity Drug Trial Results Disappoint Amid Lilly, Novo Competition
Boehringer Ingelheim's obesity drug trial results show a 13.1% weight loss, a disappointing outcome in the competitive market dominated by Eli Lilly…
Boehringer Ingelheim's obesity drug trial results show a 13.1% weight loss, a disappointing outcome in the competitive market dominated by Eli Lilly…